Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Two-staged, Phase 2/3, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of REC-2282 in Participants With Progressive NF2 Mutated Meningiomas

Next Previous
X
Search
Trial Profile

A Two-staged, Phase 2/3, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of REC-2282 in Participants With Progressive NF2 Mutated Meningiomas

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 15 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs REC 2282 (Primary)
  • Indications Neurofibromatosis 2
  • Focus Therapeutic Use
  • Acronyms POPLAR; POPLAR-NF2
  • Sponsors Recursion Pharmaceuticals

    • Most Recent Events

    • 09 May 2024 According to a Recursion Pharmaceuticals media release, enrollment in adults expected to complete in Q2 2024.
    • 27 Feb 2024 According to a Recursion Pharmaceuticals media release, enrollment in adults expected to complete in H1 2024 and preliminary efficacy data in Q4 2024.
    • 19 Jan 2024 Planned number of patients changed from 90 to 92.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top